Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » Medicine » Neurologic Disorders » Perspectives on Alzheimer's Disease Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Fighting for a Gender[ed] Identity: An Ethnographic Examination of White Collar Boxers
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Mild Cognitive Impairment: An Overview (pp. 103-113)
Tell A Friend
Tell someone you know about this product.
Mild Cognitive Impairment: An Overview (pp. 103-113) $100.00
Authors:  (M.S. Henry, D. Craig, J.A. Johnston, A.P. Passmore and B. McGuinness)
In an ageing population with a projected large increase in the burden of Alzheimer‘s disease (AD) on patients, carers and health care provision, there has recently been great interest in the concept of identifying those high-risk individuals in the area between normal cognition and dementia for whom early treatment may be beneficial in slowing or even halting progression of cognitive decline.
Mild cognitive impairment (MCI) is a syndrome defined as cognitive decline greater than expected for an individual‘s age and education level, but with preserved activities of daily living. Studies have confirmed an increased rate of progression to dementia in patients diagnosed with MCI (approximately 12% per year), with particular interest in the subtype of amnestic MCI (a-MCI) as a precursor to AD. Indeed some authors have described the clinical phenotype of amnestic MCI as mirroring that of fully expressed AD, only reflecting a milder stage.
Diagnostic testing and elucidation of early disease markers are important evolving concepts in the field of MCI research. Neuroimaging studies with MRI have shown characteristic patterns of atrophy, especially in medial temporal lobes, and white matter changes in MCI patients. Metabolic imaging with positron emission tomography (PET) is a promising modality for detection of functional abnormalities. Cerebrospinal fluid biomarkers such as beta-amyloid and tau may help to identify those patients at risk of decline from MCI to AD. Other studies have associated severity of episodic memory deficits and neuropsychiatric symptoms with progression to dementia.
MCI, however, is a heterogeneous condition which presents problems with respect to diagnosis and study variability. We discuss current thinking regarding the aetiology, diagnostic criteria and sub-typing of this syndrome. 

Available Options:
This Item Is Currently Unavailable.
Special Focus Titles
01.Heart Failure: What a Non-Heart Failure Specialist Needs to Know
02.Bottle-Feeding: Perceptions, Practices, and Health Outcomes
03.Between Success and Failure: Assessment of Aspirations and Risk (CD Included)
04.Understanding Left and Right: An Illustrated Guide to the Political Divide
05.Phytoremediation: Methods, Management and Assessment
06.“Waste-to-Profit” (W-t-P): Value added Products to Generate Wealth for a Sustainable Economy. Volume 1
07.The Impact and Implications of Crisis: A Comprehensive Approach Combining Elements of Health and Society
08.When "We" Are Stressed: A Dyadic Approach to Coping with Stressful Events
09.The Man Brand: Why Public Campaigns Hide Half of Intimate Partner Violence
10.The Life of Abraham Lincoln: Drawn from Original Sources and Containing Many Speeches, Letters and Telegrams Hitherto Unpublished. Volume One
11.Life of Charles Dickens
12.The Inventions and Discoveries of the World’s Most Famous Scientists

Nova Science Publishers
© Copyright 2004 - 2018

Mild Cognitive Impairment: An Overview (pp. 103-113)